Evidence map›Paper›PMID 42186168›Full record

ArticleActa dermato-venereologica2026

Comparative Efficacy of JAK Inhibitors in Acute vs Nonacute Alopecia Areata: A Retrospective Cohort Study.

Ruxin Ji, Man Zhang, Tian Tian, Jundong Huang, Jia Jian, Min Li, Xiaobing Liang, Zhixiang Zhao, Fangfen Liu, Wei Shi and 4 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta dermato-venereologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Ritlecitinib: A Review in Severe Alopecia Areata.American journal of clinical dermatology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ruxin Ji *Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China.
Man Zhang *Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China.
Tian Tian *Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China.
Jundong HuangDepartment of Dermatology, Xiangya Hospital, Central South University, Changsha, China.
Jia JianDepartment of Dermatology, Xiangya Hospital, Central South University, Changsha, China.
Min LiDepartment of Dermatology, Xiangya Hospital, Central South University, Changsha, China.
Xiaobing LiangDepartment of Dermatology, Xiangya Hospital, Central South University, Changsha, China.
Zhixiang ZhaoDepartment of Dermatology, Xiangya Hospital, Central South University, Changsha, China; Hunan Key Laboratary of Aging Biology, Xiangya Hospital, Central South University, Changsha, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China; FuRong Laboratory, Changsha, China.
Fangfen LiuDepartment of Dermatology, Xiangya Hospital, Central South University, Changsha, China; Hunan Key Laboratary of Aging Biology, Xiangya Hospital, Central South University, Changsha, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China; FuRong Laboratory, Changsha, China.
Wei ShiDepartment of Dermatology, Xiangya Hospital, Central South University, Changsha, China; Hunan Key Laboratary of Aging Biology, Xiangya Hospital, Central South University, Changsha, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China; FuRong Laboratory, Changsha, China.
Ji LiDepartment of Dermatology, Xiangya Hospital, Central South University, Changsha, China; Hunan Key Laboratary of Aging Biology, Xiangya Hospital, Central South University, Changsha, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China; FuRong Laboratory, Changsha, China.
Shixin DuanDepartment of Dermatology, Xiangya Hospital, Central South University, Changsha, China; Hunan Key Laboratary of Aging Biology, Xiangya Hospital, Central South University, Changsha, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China; FuRong Laboratory, Changsha, China.
Aike WuDepartment of Dermatology, Xiangya Hospital, Central South University, Changsha, China; Hunan Key Laboratary of Aging Biology, Xiangya Hospital, Central South University, Changsha, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China; FuRong Laboratory, Changsha, China. wak_xy@csu.edu.cn.
Yan TangDepartment of Dermatology, Xiangya Hospital, Central South University, Changsha, China; Hunan Key Laboratary of Aging Biology, Xiangya Hospital, Central South University, Changsha, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China; FuRong Laboratory, Changsha, China. ytang_xy@csu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite advancements in systemic treatments, the efficacy of Janus kinase (JAK) inhibitors in acute versus non-acute alopecia areata (AA) remains poorly defined, necessitating comparative studies to optimize therapeutic strategies. This retrospective, single-centercentre cohort study included 158 AAalopecia areata patients treated with JAKJanus kinase inhibitors (tofacitinib or ritlecitinib) between 2021 and 2025, aimed at evaluating clinical outcomes and identifying predictors of super-responder (SR) status. Patients were stratified into acute (n=41) and non-acute (n=117) groups based on disease duration and treatment history, with efficacy assessed using the Severity of Alopecia Tool (SALT) through week 24. Our findings demonstrate that patients with acute AAalopecia areata achieved significantly superior outcomes, with 65 % reaching SALT100 by week 24 compared to 39.5 % in the non-acute group (p=0.041). Binary logistic regression analysis further identified tofacitinib treatment (OR=2.883, p=0.009) and mild-to-moderate baseline severity (OR=2.802, p=0.015) as significant predictors of SRsuper-responder status, while acute AAalopecia areata status showed borderline predictive value (OR=2.418, p=0.098). Although limited by its single-centercentre design and sample size, this study underscores that early intervention with JAKJanus kinase inhibitors in acute AAalopecia areata leads to enhanced hair regrowth, emphasizing the critical importance of timely clinical management.

Indexed as

Alopecia AreataJanus Kinase InhibitorsPiperidinesPyrimidinesPyrrolesAcute DiseaseAdultFemaleHumansMaleMiddle AgedRetrospective StudiesSeverity of Illness IndexTime FactorsTreatment OutcomeJanus Kinase InhibitorsPiperidinesPyrimidinesPyrrolestofacitinib

Identifiers

PMID42186168
PMCPMC13201215

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.